TransMedics Group is changing its financial leadership as it prepares for another phase of expansion in organ transplantation technology. The company said Fernando Araujo will become chief financial officer on September 21, succeeding Gerardo Hernandez, while reiterating its 2026 revenue outlook of $737 million to $757 million. The appointment comes as TransMedics expands its Organ Care System (OCS), transplant logistics operations and international commercial footprint.
TransMedics is bringing in a finance executive with experience at GE HealthCare, General Electric and 3M as the medical technology company attempts to scale an increasingly integrated organ-transplantation business.
Fernando Araujo will take over as chief financial officer on September 21, 2026. According to TransMedics, Araujo has more than two decades of public-company finance experience spanning healthcare, industrial and energy businesses. Most recently, he was CFO of GE HealthCare’s Advanced Imaging Solutions segment, a business the company described as having approximately $16 billion in scale.
The appointment is more significant than a routine CFO transition because TransMedics is moving beyond selling a medical device into building a broader transplantation platform combining organ preservation technology, clinical services and logistics.
At the center of that strategy is the Organ Care System, or OCS, which uses portable warm perfusion to keep donor organs functioning outside the body during transportation and enable assessment before transplantation. The approach differs from conventional static cold storage, potentially allowing transplant teams to consider organs that may otherwise be difficult to transport or evaluate.
TransMedics reported $605.5 million in revenue for 2025, up 37% from the previous year, while completing 5,139 U.S. OCS cases, a 38% increase from 2024.
The company is now targeting another year of double-digit growth. Its reiterated 2026 revenue guidance of $737 million to $757 million implies approximately 22% to 25% year-over-year growth based on the company’s stated outlook. TransMedics said the guidance excludes revenue from its recent strategic investment in Germany-based PAD Aviation Service.
That investment highlights an important part of the company’s strategy: transplantation increasingly depends on logistics as much as clinical technology. In July, TransMedics completed its investment in PAD Aviation, describing it as a foundation for a dedicated European air and ground organ-transplant logistics network.
The model could give TransMedics greater control over the operational infrastructure surrounding its OCS technology. Instead of relying entirely on conventional transportation networks and third-party coordination, the company is building an ecosystem designed around time-sensitive organ movement.
That is particularly relevant in a market where demand remains substantial. The 2024 OPTN/SRTR Annual Data Report recorded 167,230 unique patients on U.S. solid-organ transplant waiting lists during the year, with 70,600 people added during 2024. More than 45,000 transplants were performed that year.
TransMedics’ challenge is therefore not simply to increase equipment adoption. It must scale manufacturing, clinical support, transportation, international operations and financial controls simultaneously while maintaining the reliability required in a life-critical environment.
Araujo’s background could be relevant to that transition. His previous roles included finance leadership for GE HealthCare’s global operations and healthcare businesses in Latin America and North America. TransMedics says he will support operating leverage, international expansion and the development of its product pipeline.
That pipeline includes OCS Kidney and OCS Gen-3.0, while the company is also seeking to increase utilization of its heart and lung platforms. The strategy suggests TransMedics is attempting to expand from a specialized transplantation technology provider into a broader infrastructure business for organ procurement and delivery.
The competitive landscape is also evolving. Organ preservation has historically relied heavily on cold-storage methods, while normothermic and other machine-perfusion technologies are being developed to preserve organs under more physiologically relevant conditions. Clinical research involving TransMedics’ OCS Heart has examined outcomes across thousands of transplant procedures, including organs from extended-criteria and circulatory-death donors.
For investors, the CFO transition therefore arrives at an operational inflection point. Revenue growth remains strong, but sustaining that trajectory will require TransMedics to demonstrate that its infrastructure investments can generate greater scale without eroding profitability.
Hernandez will not leave the company. Instead, he will become Commercial Strategic Advisor, LATAM, where TransMedics says he will help develop its Latin American expansion. The shift effectively separates financial scaling from regional commercial development while retaining his experience inside the organization.
The company’s next major investor-facing checkpoints are its third-quarter results and the September appearances at the Morgan Stanley Global Healthcare Conference and Baird Global Healthcare Conference.
For the broader healthcare technology market, the announcement illustrates a larger shift: medical-device companies with differentiated technology increasingly need software-like infrastructure, specialized logistics and international operating capabilities to turn a product into a scalable platform.
Market Landscape
TransMedics sits at the intersection of medical technology, healthcare logistics, organ-preservation technology and platform-based clinical services rather than traditional financial technology.
Its growth strategy reflects a broader healthcare-technology trend in which specialized devices are increasingly paired with data, logistics and service infrastructure. The company’s National OCS Program combines its organ-preservation technology with procurement and transplantation logistics, while its European strategy is designed to extend that model geographically.
The scale of the transplant market provides a substantial underlying need. U.S. transplant waiting lists continue to represent a large unmet demand, with heart, lung and kidney candidates accounting for significant portions of the national system.
From a GlobalFinTechEdge perspective, the more relevant financial-technology issue is capital allocation and infrastructure economics: companies such as TransMedics increasingly require sophisticated financial operations as they move from device sales toward integrated, asset-intensive healthcare platforms.
Top Insights
- TransMedics is pairing a CFO transition with a broader push into organ-preservation technology, logistics infrastructure and international commercial expansion.
- The company reiterated 2026 revenue guidance of $737 million to $757 million, implying roughly 22% to 25% annual growth.
- Its OCS platform is increasingly supported by dedicated logistics infrastructure, including the company’s European investment in PAD Aviation.
- TransMedics completed 5,139 U.S. OCS cases in 2025, up 38% from the previous year, according to company-reported results.
- Araujo’s GE HealthCare background could help TransMedics manage financial complexity as its technology and geographic footprint expand.
Get in touch with our fintech expert
